Analyst Price Targets — ANRO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 16, 2026 2:56 pm | Andrew Tsai | Jefferies | $35.00 | $24.78 | StreetInsider | Alto Neuroscience (ANRO) PT Raised to $35 at Jefferies |
| February 17, 2026 12:13 pm | Thomas Shrader | BTIG | $28.00 | $16.89 | TheFly | Alto Neuroscience price target raised to $28 from $27 at BTIG |
| October 20, 2025 3:05 pm | — | Robert W. Baird | $16.00 | $11.07 | TheFly | Alto Neuroscience price target raised to $16 from $10 at Baird |
| October 23, 2024 6:24 am | Brian Skorney | Robert W. Baird | $10.00 | $14.53 | StreetInsider | Alto Neuroscience (ANRO) PT Lowered to $10 at Baird |
| June 20, 2024 12:50 pm | Brian Skorney | Robert W. Baird | $32.00 | $11.11 | StreetInsider | Baird on Alto Neuroscience (ANRO): 'Incrementally positive on Phase 2 CIAS initiation' |
Latest News for ANRO
Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price gapped down before the market opened on Thursday after Robert W. Baird lowered their price target on the stock from $41.00 to $38.00. The stock had previously closed at $23.41, but opened at $20.00. Robert W. Baird currently has an outperform rating on the stock.
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced topline data from its Phase 2 proof-of-concept (POC) clinical trial evaluating ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS), and provided an update on the Company's pipeline…
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, announced today that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities in a private placement financing (the “PIPE”) for…
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the full year ended December 31, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. “Alto enters 2026…
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in a virtual fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 12:00pm ET. The…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ANRO.
U.S. House Trading
No House trades found for ANRO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.